Modality
Small Molecule
MOA
BCL-2i
Target
KRASG12D
Pathway
T-cell
Breast Ca
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
~Mar 2017
→ ~Jun 2018
Phase 2
Sep 2018
→ May 2031
Phase 2Current
NCT06107217
787 pts·Breast Ca
2018-09→2031-05·Terminated
787 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-05-175.1y awayPh3 Readout· Breast Ca
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2/3
Termina…
Catalysts
Ph3 Readout
2031-05-17 · 5.1y away
Breast Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06107217 | Phase 2/3 | Breast Ca | Terminated | 787 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D |